Member Info for Rocket79

Agree what an opportunity at this price.

The growth rates of our new partner Tempus AI....

Q2 2025 Revenue $314.6 million +89.6% YoY2

Genomics Revenue $241.8 million +115% YoY2

Full-Year Revenue Forecast $1.26 billion +80% YoY2

Adjusted EBITDA (2025) $5 million Up from –$110M in 2024

Stock Performance (YTD) +157.1% Outpaced S&P 500’s 12%

Tempus AI isn’t just growing—it’s accelerating, with improving margins and expanding into cardiology, radiology, and mental health. It’s one of the few AI-driven healthcare firms showing real revenue and profitability momentum, not just hype!!

Buy the dips this is going a lot higher. This was over 15p on Tempus News and after update yesterday no reason why we should not be above that.Good luck

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

Massive buys going through at 11.5p they know this is going to rerate.

15p first stop then onto 20p...

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Ignore derampers trying to get in cheaper... as has been mentioned figures will gmalsi be updated as the collaboration progresses.

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

The growth rates of our new partner Tempus AI....

Q2 2025 Revenue $314.6 million +89.6% YoY2

Genomics Revenue $241.8 million +115% YoY2

Full-Year Revenue Forecast $1.26 billion +80% YoY2

Adjusted EBITDA (2025) $5 million Up from –$110M in 2024

Stock Performance (YTD) +157.1% Outpaced S&P 500’s 12%

Tempus AI isn’t just growing—it’s accelerating, with improving margins and expanding into cardiology, radiology, and mental health. It’s one of the few AI-driven healthcare firms showing real revenue and profitability momentum, not just hype!!

Agree never mine 15p this will be 20p in a few weeks imo

: Only way is up now23 Sep 2025 09:13

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Profilesrocket79

Member Info for Rocket79

Posts

(Last 30 Days)

108

Posts

(All Time)

3,362

Last Post

24th Sep 2025

Member Since

9th Sep 2009

Share Chat Post Distribution over the last 30 days

Chart

Pie chart with 4 slices.

End of interactive chart.

Share Chat

General Chat

Private Messaging

Rocket79

Posted in: RENX

Posts: 3,362

Price: 9.70

Strong Buy

RE: RnsToday 14:41

This is going to rerate....

Rocket79

Posted in: RENX

Posts: 3,362

Price: 9.10

Strong Buy

RE: BoD23 Sep 2025 11:13

Bought more at 9p. What a bargain. Good luck all

Rocket79

Posted in: RENX

Posts: 3,362

Price: 9.15

Strong Buy

RE: Only way is up now23 Sep 2025 09:18

Educated buyers coming in now as the short term trader sells weaken. This will probably end up today. This should not have dropped. Institutions and directors just backed the company putting in millions at a higher price.

Rocket79

Posted in: RENX

Posts: 3,362

Price: 9.15

Strong Buy

RE: Only way is up now23 Sep 2025 09:13

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

This is going to rerate....

Bought more at 9p. What a bargain. Good luck all

Educated buyers coming in now as the short term trader sells weaken. This will probably end up today. This should not have dropped. Institutions and directors just backed the company putting in millions at a higher price.

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Long term growth story stonger than ever.

The institutions buying in yesterday would have ofcourse seen the presentation. Hence it was over subscribed... Strong Buy. Can even buy in lower now due to short term traders, but not for long imo